---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-015686"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:29:52.138099+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma Q1 revenue $8.0M (+50% YoY); acquires PKU GOLIKE; submits NDA for ET-400

## Summary
- Q1 2024 revenue $8.0M, up 50% YoY; net loss narrowed to $0.8M from $2.7M.
- Acquired U.S. rights to PKU GOLIKE for PKU; market ~$100M; targeting $10M annual sales.
- Submitted NDA for ET-400 (hydrocortisone oral solution); potential approval Q1 2025; peak sales >$50M combined.
- Launched Nitisinone in Feb 2024; $50M market; cross-selling opportunities with Carglumic Acid and PKU GOLIKE.

## SEC filing metadata
- accession: 0001437749-24-015686
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774924015686/0001437749-24-015686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774924015686/eton20240426_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-015686
- JSON: https://secwatch.observer/filing/0001437749-24-015686.json
- Plain text: https://secwatch.observer/filing/0001437749-24-015686.txt

## Key facts
- Earnings Releases
  Eton Pharmaceuticals, Inc. reported first quarter ended March 31, 2024 results: revenue $8.0 million, net income Net loss for the first quarter of 2024 was $0.8 million, EPS $0.03 per basic and diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $8.0 million
  - Net income: Net loss for the first quarter of 2024 was $0.8 million
  - EPS: $0.03 per basic and diluted share
  - Result: reported results
  source text: Net revenues for the first quarter of 2024 were $8.0 million compared with $5.3 million in the prior year period, an increase of 50%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000143774924015686/0001437749-24-015686-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.